artificial heart

Abstract

The present invention relates to an artificial heart, which includes a global balloon beating system and a myocardial regeneration induction system. The former includes a ventricular sheath, a balloon and a power system. The ventricular sheath is wrapped outside the ventricle, and the balloon is placed between the ventricle and the ventricular sheath. The gas catheter connects the balloon and the power system; when the ventricle contracts, the power system inflates the balloon; when the ventricle relaxes, the power system deflates the balloon; the latter includes a laser fiber and a laser, and one end of the laser fiber is connected to the laser, The other end is positioned on the outer surface of the ventricle, the laser emits laser light according to preset parameters, and the laser irradiates the outer surface of the ventricle through the laser fiber to induce regeneration of cardiomyocytes. The artificial heart provided by the invention can induce myocardial cell regeneration to improve the structure of the myocardium, avoid the influence of artificial materials on the blood system, and restore the systolic and diastolic functions of the heart; it has strong operability and a wide range of applications; it can also be used as a permanent assisting equipments.

Description

technical field [0001] The invention relates to the field of medical devices, in particular to an artificial heart. Background technique [0002] Heart failure (hereinafter referred to as heart failure) is the final destination of most cardiovascular diseases, and it is a common, high medical expenditure and potentially fatal disease. China's 2011 cardiovascular disease report pointed out that there are currently about 4.2 million heart failure patients in my country; in developed countries, about 2% of adults suffer from heart failure, and those over the age of 65 increase to 6- 10%. And that number is increasing as the global population ages. In the past 30 years, despite many advances in the diagnosis and treatment of heart failure, the mortality rate of heart failure remains high. The risk of death was 35% in the first year after heart failure diagnosis and decreased to 10% each year thereafter. Even with the best treatment, the annual mortality rate from heart failur...

AI Technical Summary

Problems solved by technology

However, left ventricular assist devices still have significant limitations.

First, the device can only partially improve the function of the failing heart, causing irreversible damage to the myocardium and heart valves

Secondly, this method has a series of contraindications and complicated process, so the practical application range is very limited

Third, this method can only temporarily replace the left heart pumping blood, and its service life is limited

Finally, the current ventricular assist device needs to be in direct contact with blood, and a series of fatal complications such as bleeding, thrombus, hemolysis, infection, and immune response will inevitably occur

Images